Y Mabs Therapeutics Stock Fundamentals
| YMAB Stock | USD 6.19 0.04 0.65% |
Y mAbs Therapeutics fundamentals help investors to digest information that contributes to Y MAbs' financial success or failures. It also enables traders to predict the movement of YMAB Stock. The fundamental analysis module provides a way to measure Y MAbs' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Y MAbs stock.
YMAB |
Y mAbs Therapeutics Company Shares Outstanding Analysis
Y MAbs' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Y MAbs Shares Outstanding | 44.79 M |
Most of Y MAbs' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Y mAbs Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Y mAbs Therapeutics has 44.79 M of shares currently outstending. This is 75.19% lower than that of the Biotechnology sector and 58.08% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 92.17% higher than that of the company.
Y mAbs Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Y MAbs's current stock value. Our valuation model uses many indicators to compare Y MAbs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Y MAbs competition to find correlations between indicators driving Y MAbs's intrinsic value. More Info.Y mAbs Therapeutics is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Y MAbs' earnings, one of the primary drivers of an investment's value.YMAB Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Y MAbs' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Y MAbs could also be used in its relative valuation, which is a method of valuing Y MAbs by comparing valuation metrics of similar companies.Y MAbs is currently under evaluation in shares outstanding category among its peers.
YMAB Fundamentals
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.43) % | ||||
| Current Valuation | 208.41 M | ||||
| Shares Outstanding | 44.79 M | ||||
| Shares Owned By Insiders | 12.44 % | ||||
| Shares Owned By Institutions | 72.15 % | ||||
| Number Of Shares Shorted | 3.74 M | ||||
| Price To Book | 2.98 X | ||||
| Price To Sales | 3.28 X | ||||
| Revenue | 84.82 M | ||||
| Gross Profit | 75.11 M | ||||
| EBITDA | (24.94 M) | ||||
| Net Income | (21.43 M) | ||||
| Cash And Equivalents | 133.66 M | ||||
| Cash Per Share | 3.06 X | ||||
| Total Debt | 1.42 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.23 X | ||||
| Book Value Per Share | 2.06 X | ||||
| Cash Flow From Operations | (27.23 M) | ||||
| Short Ratio | 8.72 X | ||||
| Earnings Per Share | (0.54) X | ||||
| Price To Earnings To Growth | 0.04 X | ||||
| Target Price | 20.36 | ||||
| Number Of Employees | 100 | ||||
| Beta | 0.67 | ||||
| Market Capitalization | 277.24 M | ||||
| Total Asset | 127.87 M | ||||
| Retained Earnings | (457.47 M) | ||||
| Working Capital | 90.98 M | ||||
| Net Asset | 127.87 M |
About Y MAbs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Y mAbs Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Y MAbs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Y mAbs Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Y-Mabs Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 148 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock:Check out Y MAbs Piotroski F Score and Y MAbs Altman Z Score analysis. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.